How I Diagnose Primary Cutaneous Marginal Zone Lymphoma
| Autor: | Steven H. Swerdlow, Sarah E. Gibson |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Heavy chain
Pathology medicine.medical_specialty Skin Neoplasms business.industry Lymphoma diagnosis MALT lymphoma Lymphoma B-Cell Marginal Zone General Medicine Middle Aged medicine.disease Lymphoma 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis medicine Humans Primary cutaneous marginal zone lymphoma Female Marginal zone B-cell lymphoma Differential diagnosis business Aged Primary cutaneous marginal zone B-cell lymphoma |
| Zdroj: | American Journal of Clinical Pathology. 154:428-449 |
| ISSN: | 1943-7722 0002-9173 |
| DOI: | 10.1093/ajcp/aqaa116 |
| Popis: | Objectives Primary cutaneous marginal zone lymphoma (PCMZL) is 1 of the 3 major subtypes of primary cutaneous B-cell lymphoma. The diagnosis of PCMZL may be challenging, as the differential diagnosis includes benign cutaneous lymphoproliferations as well as other primary or secondary cutaneous B-cell or T-cell lymphomas. This review describes our approach to the diagnosis of PCMZL. Methods Two cases are presented that illustrate how we diagnose each of the 2 subtypes of PCMZL. The clinicopathologic features of PCMZL and the ways in which these cases can be distinguished from both benign and other neoplastic entities are emphasized. Results A definitive diagnosis of PCMZL requires the incorporation of histologic and immunophenotypic features, molecular genetic studies in some cases, and just as importantly, clinical findings. Emerging data suggest that the heavy chain class-switched cases may be more like a clonal chronic lymphoproliferative disorder. Conclusions The 2 subtypes of PCMZL create different diagnostic challenges and require the use of a multiparameter approach. Although very indolent, it is important to distinguish PCMZLs from reactive proliferations, because they frequently recur and may require antineoplastic therapies. It is also critical to distinguish PCMZLs from other B- or T-cell lymphomas so that patients are properly evaluated and not overtreated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|